Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Michelson, D. Articles by Tepner, R. Search for Related Content PubMed Citation Articles by Michelson, D. Articles by Tepner, R. Sexual Disorders Antidepressants

Female Sexual Dysfunction Associated With Antidepressant Administration: A Randomized, Placebo-Controlled Study of Pharmacologic Intervention

OBJECTIVE: Few controlled trials of pharmacologic intervention in women with antidepressant-associated sexual dysfunction have been reported, and there is uncertainty about the usefulness of putative treatments and the assessment methodologies. The authors evaluated the efficacy of buspirone and amantadine in the treatment of sexual dysfunction associated with fluoxetine administration. METHOD: Women who had been successfully treated with fluoxetine for at least 8 weeks and who had reported a deterioration in sexual function not present before the initiation of fluoxetine entered a 4-week assessment period. After assessment they were randomly assigned to an 8-week treatment trial with buspirone (N=19), amantadine (N=18), or placebo (N=20). Outcomes were assessed by using a patient-rated daily diary and a clinician-rated structured interview. RESULTS: While the amantadine-treated women did report significantly greater improvements in energy levels than women in the placebo group, all treatment groups experienced improvement in overall sexual function as well as in most individual measures. There were no statistically significant differences among the three groups. CONCLUSIONS: Neither buspirone nor amantadine was more effective than placebo in ameliorating antidepressant-associated sexual dysfunction. All groups experienced marked nonspecific improvement during treatment, which suggests the importance of placebo-controlled trials for this condition.

This article has been cited by other articles:

				D. Baldwin, J. Hutchison, K. Donaldson, B. Shaw, and A. Smithers Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670 J Psychopharmacol, January 1, 2008; 22(1): 55 - 63. [Abstract] [PDF]

				D. Baldwin and A. Mayers Sexual side-effects of antidepressant and antipsychotic drugs Advan. Psychiatr. Treat., May 1, 2003; 9(3): 202 - 210. [Abstract] [Full Text] [PDF]

				P. S. Masand, A. K. Ashton, S. Gupta, and B. Frank Sustained-Release Bupropion for Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Am J Psychiatry, May 1, 2001; 158(5): 805 - 807. [Abstract] [Full Text]

				D. S Baldwin Depression and sexual dysfunction Br. Med. Bull., March 1, 2001; 57(1): 81 - 99. [Abstract] [Full Text] [PDF]

				T. TERAO Female Sexual Dysfunction and Antidepressant Use Am J Psychiatry, February 1, 2001; 158(2): 326- - 327. [Full Text]

				C. M. Meston and P. F. Frohlich The Neurobiology of Sexual Function Arch Gen Psychiatry, November 1, 2000; 57(11): 1012 - 1030. [Abstract] [Full Text] [PDF]

				SSRIs, Sex, and the Placebo Effect Journal Watch Psychiatry, June 1, 2000; 2000(601): 17 - 17. [Full Text]

				SSRIs, Sex, and the Placebo Effect Journal Watch Women's Health, April 1, 2000; 2000(401): 18 - 18. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us